Reaction
Ear Haemorrhage reporting signals
As of the last recalculation, Ear Haemorrhage appears in 1,995 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is EMICIZUMAB (PRR 27.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Emicizumab | 32 | 27.4 | 27.5 |
| Ibrutinib | 134 | 18.5 | 18.5 |
| Prasugrel Hydrochloride | 10 | 10.3 | 10.3 |
| Warfarin Sodium | 38 | 8.7 | 8.7 |
| Rivaroxaban | 161 | 8.7 | 8.7 |
| Acalabrutinib | 9 | 7.8 | 7.8 |
| Ticagrelor | 23 | 7.6 | 7.6 |
| Sotalol Hydrochloride | 12 | 7.6 | 7.6 |
| Warfarin | 87 | 7.4 | 7.4 |
| Primidone | 7 | 7.2 | 7.2 |
| Avapritinib | 6 | 5.2 | 5.2 |
| Dabigatran Etexilate Mesylate | 33 | 4.8 | 4.8 |
| Dabigatran Etexilate | 33 | 4.5 | 4.5 |
| Rocuronium Bromide | 5 | 4.4 | 4.4 |
| Romiplostim | 6 | 4.2 | 4.2 |
| Dofetilide | 4 | 4.0 | 4.0 |
| Lifitegrast | 6 | 3.8 | 3.8 |
| Nintedanib | 11 | 3.7 | 3.7 |
| Apalutamide | 4 | 3.6 | 3.6 |
| Vismodegib | 3 | 3.5 | 3.5 |
| Cenegermin-Bkbj | 3 | 2.6 | 2.6 |
| Relugolix | 5 | 2.2 | 2.2 |
| Ledipasvir And Sofosbuvir | 4 | 2.2 | 2.2 |
| Bimekizumab | 4 | 2.0 | 2.0 |